Key result
Inclisiran, a twice-yearly small interfering RNA agent, consistently achieves LDL-C reductions exceeding 50% and demonstrates a favourable tolerability profile for dyslipidaemia management.
Why the study?
Does inclisiran improve LDL-C reduction in high-risk patients with inadequately controlled dyslipidemia?
Does inclisiran improve LDL-C reduction in high-risk patients with inadequately controlled dyslipidemia?
Inclisiran offers a potent, twice-yearly dosing option for LDL-C reduction in high-risk patients, though cardiovascular outcome data are still pending.
Compelling evidence linking low-density lipoprotein cholesterol (LDL-C) reduction to decreased mortality has positioned LDL-C lowering as a central strategy in the prevention of atherosclerotic cardiovascular disease (ASCVD). Nonetheless, despite widespread statin use, an estimated 10–20% of individuals at high or very high cardiovascular risk fail to attain guideline-recommended LDL-C targets. This persistent treatment gap underscores the need for more potent and durable lipid-lowering strategies, particularly among patients with familial hypercholesterolemia (FH) and those with established ASCVD whose LDL-C levels remain inadequately controlled despite optimized combination therapy, including statins, ezetimibe, and proprotein convertase subtilisin–kexin type 9 (PCSK9) monoclonal antibodies. Inclisiran, a first-in-class small interfering RNA agent, addresses this unmet need by selectively inhibiting hepatic synthesis of PCSK9, thereby enhancing low-density lipoprotein receptor (LDLR) recycling and accelerating LDL-C clearance. Nevertheless, thus far, no cardiovascular outcome trial (CVOT) has been available. With a convenient twice-yearly dosing regimen, inclisiran consistently achieves LDL-C reductions exceeding 50% and demonstrates a favourable tolerability profile, offering an effective and patient-friendly advancement in dyslipidaemia management.
No takes yet. Share an insight, caveat, or question.
Santoso et al. (2026) conducted a review in Dyslipidaemia and ASCVD. Inclisiran was evaluated on LDL-C reduction. Inclisiran, a twice-yearly small interfering RNA agent, consistently achieves LDL-C reductions exceeding 50% and demonstrates a favourable tolerability profile for dyslipidaemia management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: